Adm1n: Created page with "TM-38837 is a small molecule inverse agonist/antagonist of the CB1 cannabinoid receptor, with peripheral selectivity. It is being developed for the treatment of obesit..."

2015-02-16T15:07:56Z

Created page with "TM-38837 is a small molecule inverse agonist/antagonist of the CB1 cannabinoid receptor, with peripheral selectivity. It is being developed for the treatment of obesit..."

New page

TM-38837 is a small molecule inverse agonist/antagonist of the [[CB1]] [[cannabinoid receptor]], with peripheral selectivity. It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma.The company has announced phase I clinical trials.

TM-38837 is among the first of a new generation of cannabinoid receptor antagonist designed to avoid the central nervous system liabilities of the first generation CB1 receptor antagonists such as [[rimonabant]].

==See also==

* [[AM-6545]]

TM-38837 - Revision history

Adm1n: Created page with "TM-38837 is a small molecule inverse agonist/antagonist of the CB1 cannabinoid receptor, with peripheral selectivity. It is being developed for the treatment of obesit..."